163152-42-9

Basic information

• Product Name: Adenosine, 2-chloro-N-[(3-iodophenyl)methyl]-, 2',3',5'-tribenzoate
• CAS NO: 163152-42-9
• Molecular Formula: C38H29ClIN5O7
• Molecular Weight: 830.035
• Mol File: 163152-42-9.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Adenosine, 2-chloro-N-[(3-iodophenyl)methyl]-, 2',3',5'-tribenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Adenosine, 2-chloro-N-[(3-iodophenyl)methyl]-, 2',3',5'-tribenzoate(163152-42-9)
• EPA Substance Registry System: Adenosine, 2-chloro-N-[(3-iodophenyl)methyl]-, 2',3',5'-tribenzoate(163152-42-9)

Safety Data

• Hazardous Substances Data: 163152-42-9(Hazardous Substances Data)

Upstream product

• 6974-32-9 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose 
• 15373-23-6 (2R,3R,4R,5R)-2-((benzoyloxy)methyl)-5-(2,6-dichloro-9H-purin-9-yl)tetrahydrofuran-3,4-diyl dibenzoate 
• 3718-88-5 3-iodobenzylamine hydrochloride 
• 163042-95-3 (2-Chloro-9-trimethylsilanyl-9H-purin-6-yl)-(3-iodo-benzyl)-amine 
• 120046-86-8 2-chloro-N-⁶-(3-iodobenzyl)adenine 
• 5451-40-1 2,6 dichloropurine 

Downstream Products

• 163152-31-6 MRS 542 
• 1000980-71-1 ((3aR,4R,6R,6aR)-6-(2-chloro-6-(3-iodobenzylamino)9H-purine-9-yl) 2,2-dimethyl-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol 
• 163042-96-4 1-[2-chloro-6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-β-D-ribofuranuronamide 

Relevant articles and documents

Novel Adenine Derivatives and the Use Thereof

The present invention relates to a novel adenine derivative and a pharmaceutical use thereof and, more specifically, to a novel adenine derivative having a structure of chemical formula 1 or a pharmaceutically acceptable salt thereof, and to a composition containing the same for preventing or treating degenerative brain disease. The novel adenine derivative and the pharmaceutically acceptable salt thereof according to the present invention are adenosine A3 receptor agonists, and have an action of inhibiting the migration (or infiltration) of inflammatory cells (microglia, macrophages, neutrophils, etc.), to disease areas and the activities thereof. In addition, the adenine derivative according to the present invention was verified to suppress and treat brain injury more remarkably when compared with the known adenosine A3 receptor agonists in a cerebral ischemia experimental model, exhibit a significant effect by drug administration 10 hours after cerebral infarction, and allow long-term survival in spite of brain injury due to cerebral ischemia, and thus can be useful as an agent for treating and preventing degenerative brain disease including stroke.(AA,BB,CC,DD) Chemical formula 5COPYRIGHT KIPO 2015